Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Sep 24, 2026
Leverage Shares 2X Long SK Hynix Daily ETF (SKHX) Climbs +78% in 30 Days

Leverage Shares 2X Long SK Hynix Daily ETF (SKHX) Climbs +78% in 30 Days

Key Takeaways

  • SKHX has surged roughly 78% over the last 30 days, rebounding from about $9.89 to approximately $17.62, as underlying SK Hynix shares rallied on an AI-driven memory boom.
  • The fund delivers 2x daily leveraged exposure to a single stock, SK Hynix, so its moves are roughly double the underlying's daily changes and carry amplified volatility.
  • OpenAI's launch of a new AI model reignited demand expectations for high-bandwidth memory (HBM), lifting memory-chip stocks across the sector.
  • SK Hynix is the world's leading HBM supplier and a key provider to Nvidia, placing it at the center of AI infrastructure spending.
  • As a 2x daily leveraged single-stock ETF, SKHX carries elevated concentration and compounding risks that warrant careful monitoring.

Understanding the Leverage Shares 2X Long SK Hynix Daily ETF (SKHX)

The Leverage Shares 2X Long SK Hynix Daily ETF seeks to deliver twice (2x) the daily price performance of SK Hynix Inc. before fees and expenses. Unlike diversified funds, SKHX is a single-stock leveraged product: it holds essentially one exposure, SK Hynix, obtained through swaps and other derivatives rather than through a broad basket of equities. Its expense ratio is 0.75%. I also checked this using Tickeron’s AI Screener to see how the fund compares to other leveraged products in the space.

SK Hynix is a South Korean memory semiconductor manufacturer and the global leader in high-bandwidth memory (HBM), the specialized stacked DRAM used in AI accelerators. The company also produces conventional DRAM and NAND flash storage. Because the ETF's entire exposure sits in one highly cyclical name, its performance is driven almost entirely by memory-chip pricing, AI capital expenditure, and sentiment toward the semiconductor supercycle.

SKHX Price Performance Over the Last 30 Days and Quarter

Over the last 30 days, SKHX has climbed roughly 78%, recovering from a close near $9.89 to approximately $17.62. The advance was sharp rather than gradual, punctuated by an especially strong move in early September when the underlying SK Hynix ADR jumped more than 8% in a single session.

SKHX has traded for less than a full quarter since its July 14 debut, so a complete three-month track record does not yet exist. Since its first trading day, when the fund closed near $23.14, the ETF remains below that level despite the recent rebound. This pattern reflects the underlying stock's trajectory: SK Hynix fell sharply from its June peak through August before the September recovery, and the 2x leverage amplified both the drawdown and the rebound.

Factors Behind the Recent 30-Day Move in SKHX

The 30-day surge traces directly to renewed enthusiasm for AI memory demand. OpenAI's unveiling of a more capable AI model reinforced expectations that advanced systems will require substantially more memory capacity, lifting HBM, DRAM, and NAND demand forecasts. SK Hynix, as the leading HBM supplier, was among the primary beneficiaries, and its rally flowed through directly to SKHX.

Fundamental conditions reinforced the move. Industry data indicated that memory inventories at SK Hynix and its peers had fallen to historically low levels, while analysts projected that AI infrastructure spending would keep memory supply tight. SK Hynix also reported record quarterly results late in the period and announced a large share buyback program, further supporting sentiment. Because SKHX uses daily 2x leverage, these single-day gains in the underlying stock translated into outsized percentage moves in the fund.

Broader Context for SKHX Performance This Quarter

Although the fund itself is only about two months old, its trajectory reflects a broader rotation within the semiconductor sector. Memory stocks corrected sharply from their June highs as investors weighed the risk of an eventual supply glut and took profits after an extended rally. SK Hynix's shares fell well below their prior peak, and SKHX's leveraged structure compounded that decline during July and August.

The subsequent rebound has been driven by a return to the AI infrastructure theme. Expectations that HBM4 adoption and rising DRAM and NAND prices would extend the memory upcycle into subsequent years brought buyers back to the sector. Institutional positioning and improved sentiment around hyperscaler capital expenditure supported the recovery, which the fund's 2x structure amplified on the upside.

SKHX Outlook and Key Factors to Monitor

The outlook for SKHX is tied almost entirely to the memory cycle and AI capital expenditure. Key factors to monitor include the pace of HBM4 adoption, DRAM and NAND contract pricing, hyperscaler spending on AI infrastructure, and any signs that memory supply growth is catching up with demand. SK Hynix's earnings results and commentary on production capacity will remain central drivers, as will competitive dynamics with rivals such as Micron. From what I see, these elements deserve close attention in the months ahead.

Investors should also weigh the structural risks unique to a 2x daily leveraged single-stock ETF. Daily leverage resets can cause returns to diverge from twice the underlying's cumulative performance over longer holding periods, particularly in choppy markets. Concentration in one highly cyclical stock, currency exposure through the underlying Korean listing, and the inherent volatility of the semiconductor cycle all represent factors that could influence the fund's path over the coming months.

My Experience Using Tickeron’s AI Tools

In my own research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get a quick sense of momentum shifts in leveraged products like SKHX. The platform helps surface patterns across thousands of securities without hours of manual work. I have found it useful for cross-checking sector trends in memory chips and AI-related names before making allocation decisions. Explore the AI Daily Buy/Sell Signals if you want to incorporate similar data into your own workflow.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SKHX

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


Industry description

The investment seeks daily leveraged investment results, before fees and expenses, of two times (200%) the daily percentage change in the price of the ADR of SK Hynix. The fund invests at least 80% of its net assets (plus borrowings for investment purposes) in the underlying security and financial instruments with economic characteristics that, in combination, provide 200% daily leveraged exposure to the price of the underlying security, on a daily basis, consistent with the fund’s investment objective. It is non-diversified.
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Equity
Address
United States
Phone
N/A
Web
www.ThemesETFs.com
Interact to see
Advertisement
Kingsoft Cloud Holdings Limited (KC) shares plunged about 9% in the most recent session, extending a sharp pullback after a recent rally. The selloff reflects mounting concerns around profitability, with the company still loss-making and showing weak multi-year revenue growth.
BAK shares fell roughly 11% in the latest trading session, marking a sharp single-day drop for the Brazilian petrochemical producer The decline comes amid persistent concerns about high leverage, a weaker credit profile, and soft petrochemical margins in a challenging macro environment for chemicals​
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.